A comprehensive study capturing vision loss burden in Pakistan (1990-2025): Findings from the Global Burden of Disease (GBD) 2017 study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
12
2018
accepted:
22
04
2019
entrez:
4
5
2019
pubmed:
6
5
2019
medline:
14
1
2020
Statut:
epublish
Résumé
This study aims to provide estimates, trends and projections of vision loss burden in Pakistan from 1990 to 2025. Global Burden of Diseases, Injuries, and Risk Factors Study (GBD 2017) was used to observe the vision loss burden in terms of prevalence and Years Lived with Disability (YLDs). As of 2017, out of 207.7 million people in Pakistan, an estimated 1.12 million (95% Uncertainty Interval [UI] 1.07-1.19) were blind (Visual Acuity [VA] <3/60), 1.09 million [0.93-1.24] people had severe vision loss (3/60≤VA<6/60) and 6.79 million [6.00-7.74] people had moderate vision loss (6/60≤VA<6/18). Presbyopia was found to be the most common ocular condition that affected an estimated 12.64 million [11.94-13.41] people (crude prevalence 6.08% [5.75-6.45]; 61% female). In terms of age-standardized YLDs rate, Pakistan is ranked fourth among other South Asian countries and twenty-first among other 42 low-middle income countries (classified by World Bank), with 552.98 YLDs [392.98-752.95] per 100,000. Compared with 1990, all-age YLDs count of blindness and vision impairment increased by 55% in 2017, which is the tenth highest increase among major health loss causes (such as dietary iron deficiency, headache disorders, low back pain etc.) in Pakistan. Moreover, our statistics show an increase in vision loss burden by 2025 for which Pakistan needs to make more efforts to encounter the growing burden of eye diseases.
Identifiants
pubmed: 31050688
doi: 10.1371/journal.pone.0216492
pii: PONE-D-18-37006
pmc: PMC6499467
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0216492Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Br J Ophthalmol. 2018 Feb;102(2):220-224
pubmed: 28607177
JAMA Ophthalmol. 2015 Jan;133(1):25-31
pubmed: 25232930
PLoS One. 2015 Jul 20;10(7):e0132779
pubmed: 26192763
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4749-55
pubmed: 17065483
Br J Ophthalmol. 2007 Aug;91(8):1005-10
pubmed: 17229806
Br J Ophthalmol. 2006 Feb;90(2):135-8
pubmed: 16424519
Br J Ophthalmol. 2019 Jul;103(7):863-870
pubmed: 30209082
J Coll Physicians Surg Pak. 2005 May;15(5):291-4
pubmed: 15907241
JAMA Ophthalmol. 2015 Nov;133(11):1275-6
pubmed: 26378983
Ophthalmic Epidemiol. 2005 Oct;12(5):321-33
pubmed: 16272052
Br J Ophthalmol. 2019 Jul;103(7):885-893
pubmed: 30209083
Ophthalmic Epidemiol. 2015;22(4):237-8
pubmed: 26218105
Int J Health Plann Manage. 2018 Mar 11;:
pubmed: 29527739
JAMA Ophthalmol. 2015 Nov;133(11):1267-75
pubmed: 26379209
J Pak Med Assoc. 1992 Aug;42(8):196-8
pubmed: 1433800
Br J Ophthalmol. 2018 May;102(5):575-585
pubmed: 29545417
PLoS One. 2015 Jul 17;10(7):e0131774
pubmed: 26186605
Br J Ophthalmol. 2019 Jul;103(7):878-884
pubmed: 30209084
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234
pubmed: 29032195
Ophthalmic Epidemiol. 2003 Oct;10(4):249-58
pubmed: 14628967
Lancet Glob Health. 2017 Sep;5(9):e888-e897
pubmed: 28779882
Ophthalmic Epidemiol. 2005 Feb;12(1):19-23
pubmed: 15848917